News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
490,074 Results
Type
Article (8030)
Company Profile (152)
Press Release (481892)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166749)
Career Advice (304)
Deals (25743)
Drug Delivery (7)
Drug Development (52882)
Employer Resources (14)
FDA (9761)
Job Trends (8573)
News (238213)
Policy (17903)
Tag
2025 Best Places to Work (6)
2026 Best Places to Work (13)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Standard (3)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (1)
Academia (502)
Accelerated approval (31)
ADA (18)
Adcomms (1)
Allergies (103)
Alliances (33160)
ALS (123)
Alzheimer's disease (1029)
Antibody-drug conjugate (ADC) (340)
Approvals (10504)
Artificial intelligence (387)
ASCO (160)
Autoimmune disease (262)
Automation (34)
Bankruptcy (264)
Belgium (4)
Best Places to Work (6957)
BIO (36)
Biologics (68)
BIOSECURE Act (1)
Biosimilars (128)
BioSpace Insights (17)
Biotechnology (89)
Bispecific (34)
Bladder cancer (150)
Brain cancer (38)
Breast cancer (560)
Cancer (4184)
Cardiovascular disease (253)
Career advice (245)
Career pathing (1)
CAR-T (196)
CDC (2)
CDMO (41)
Celiac Disease (3)
Cell therapy (540)
Cervical cancer (39)
Clinical research (48695)
Collaboration (1397)
Commercialization (35)
Compensation (1681)
Complete response letters (37)
COVID-19 (781)
CRISPR (75)
CRO (1)
C-suite (875)
Cystic fibrosis (89)
Data (6805)
Denatured (4)
Depression (109)
Dermatology (107)
Diabetes (393)
Diagnostics (4294)
Digital health (45)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (180)
Drug pricing (7)
Drug shortages (3)
Duchenne muscular dystrophy (177)
Earnings (74581)
Editorial (1)
Employer branding (2)
Employer resources (14)
ESMO (240)
Events (89344)
Executive appointments (745)
Eye disease (8)
FDA (12768)
Fibrodysplasia Ossificans Progressiva (12)
Fragile X (1)
Friedreich's ataxia (21)
Frontotemporal dementia (26)
Funding (1017)
Gene editing (140)
Generative AI (15)
Gene therapy (365)
GLP-1 (325)
Government (953)
Grass and pollen (2)
Guidances (288)
Healthcare (9460)
Hematology (117)
HIV (60)
Huntington's disease (31)
Idiopathic pulmonary fibrosis (6)
IgA nephropathy (82)
Immunology and inflammation (116)
Immuno-oncology (76)
Indications (193)
Infectious disease (991)
Inflammatory bowel disease (146)
Inflation Reduction Act (4)
Influenza (90)
Intellectual property (280)
Interviews (41)
IPO (12404)
IRA (2)
Job creations (1969)
Job search strategy (235)
JPM (1)
Kidney cancer (19)
Kidney disease (93)
Layoffs (59)
Legal (5195)
Licensing (77)
Liver cancer (47)
Longevity (28)
Lung cancer (596)
Lung diease (11)
Lymphoma (285)
Machine learning (30)
Management (3)
Manufacturing (639)
Marketing (27)
MASH (132)
Medical affairs (2)
Medical device (8734)
Medtech (8938)
Melanoma (15)
Mergers & acquisitions (14502)
Metabolic disorders (805)
mRNA (86)
Multiple sclerosis (119)
Multispecific (4)
NASH (4)
Netherlands (4)
Neurodegenerative disease (251)
Neuropsychiatric disorders (41)
Neuroscience (2011)
Neurotech (2)
NextGen: Class of 2026 (3150)
Non-profit (845)
Obesity (251)
Opinion (11)
Ovarian cancer (187)
Pain (197)
Pancreatic cancer (242)
Parkinson's disease (222)
Partnered (12)
Patents (541)
Patient advocacy (4)
Patient recruitment (550)
Patient selection (62)
Peanut (34)
People (41595)
Peptides (26)
Pharmaceutical (30)
Pharmacy benefit managers (11)
Phase 1 (15731)
Phase 2 (21784)
Phase 3 (14686)
Pipeline (9223)
Policy (20)
Postmarket research (1570)
Preclinical (6633)
Press Release (34)
Prostate cancer (214)
Psychedelics (14)
Radiopharmaceuticals (208)
Rare diseases (645)
Real estate (3025)
Recruiting (6)
Regenerative medicine (18)
Regulatory (15299)
Reports (27)
Research institute (597)
Resumes & cover letters (45)
Rett syndrome (48)
RNA editing (9)
RSV (52)
Schizophrenia (112)
Series A (179)
Series B (130)
Service/supplier (5)
Sickle cell disease (70)
Spinal muscular atrophy (93)
Sponsored (5)
Startups (2021)
Stem cells (3)
Stomach cancer (3)
Substance use disorders (17)
Supply chain (58)
Switzerland (2)
Tariffs (2)
Vaccines (372)
Venture capital (18)
Weight loss (84)
Wet AMD (4)
Women's health (103)
Date
Last 7 days (407)
Last 30 days (2322)
Last 365 days (19114)
2026 (17676)
2025 (19253)
2024 (22987)
2023 (26538)
2022 (34592)
2021 (37168)
2020 (33468)
2019 (23256)
2018 (17478)
2017 (18771)
2016 (17920)
2015 (24265)
2014 (21679)
2013 (18136)
2012 (20222)
2011 (20444)
2010 (20332)
Location
Africa (234)
Alabama (81)
Alaska (2)
Arizona (333)
Arkansas (12)
Asia (18148)
Australia (2131)
California (13489)
Canada (3484)
China (598)
Colorado (556)
Connecticut (475)
Delaware (239)
Europe (24880)
Florida (2008)
Georgia (423)
Hawaii (3)
Idaho (46)
Illinois (808)
India (67)
Indiana (340)
Iowa (19)
Japan (477)
Kansas (107)
Kentucky (34)
Louisiana (30)
Maine (27)
Maryland (1326)
Massachusetts (8825)
Michigan (327)
Minnesota (626)
Mississippi (5)
Missouri (86)
Montana (20)
Nebraska (11)
Nevada (144)
New Hampshire (61)
New Jersey (2976)
New Mexico (12)
New York (3145)
North Carolina (1421)
North Dakota (4)
Northern California (6853)
Ohio (312)
Oklahoma (15)
Oregon (17)
Pennsylvania (2514)
Puerto Rico (24)
Rhode Island (32)
South America (407)
South Carolina (82)
South Dakota (1)
Southern California (5650)
Tennessee (135)
Texas (2232)
United States (43619)
Utah (407)
Vermont (1)
Virginia (170)
Washington D.C. (39)
Washington State (1026)
West Virginia (1)
Wisconsin (84)
Wyoming (1)
490,074 Results for "ascletis inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ascletis Highlights Oral and Long-Acting Injectable Anti-Obesity Preclinical Studies at ObesityWeek® 2026
November 16, 2026
·
6 min read
Press Releases
Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity
October 20, 2026
·
8 min read
Press Releases
Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity
October 26, 2026
·
5 min read
Press Releases
Ascletis to Present Study Results of Oral Small Molecule GIPR Agonist ASC48 and GLP-1R/GIPR/GCGR Triple Peptide Agonist ASC37 at ObesityWeek® 2026
November 2, 2026
·
4 min read
Press Releases
Ascletis Submits IND Application to the U.S. FDA for ASC36_37o FDC, a Potentially First-in-Class Once-Weekly Oral Quadruple Peptide Agonist Targeting Amylin Receptor, GLP-1R, GIPR and GCGR, for the Treatment of Obesity
November 17, 2026
·
4 min read
Press Releases
Ascletis’ Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with Diabetes
October 29, 2026
·
6 min read
Press Releases
Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity
September 8, 2026
·
5 min read
Press Releases
Ascletis Submits IND Application to the U.S. FDA for ASC30_39 FDC, a Potentially First-in-Class Oral Small Molecule Fixed-Dose Combination of GLP-1R Agonist and Selective Amylin Receptor Agonist, for the Treatment of Obesity
November 11, 2026
·
4 min read
Press Releases
Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs
September 7, 2026
·
3 min read
Press Releases
Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis’ Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
September 30, 2026
·
11 min read
1 of 49,008
Next